Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

D-VRd With D-R Maintenance in Transplant-Eligible NDMM: PERSEUS Cyto…

Meletios Dimopoulos

The Future of Multiple Myeloma: SCT, CAR-T, and BiTE Therapy

University of Colorado Division of Hematology

K. Sidor

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

2024 Updates on Multiple Myeloma Treatment

University of Colorado Division of Hematology

D. Sherbenou

CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Direc…

Rush University Medical Center

A. Suvannasankha

Updates on the Management of 1L Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

Key Myeloma & MGUS Updates From ASH

Memorial Sloan Kettering Cancer Center

S. Mailankody

Updates on the Management of Later Relapses of Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

Multiple Myeloma: Clinical Challenges for the Community Clinician

Winship Cancer Institute - Emory University

N. Joseph

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…

Meletios Dimopoulos

Managing Newly Diagnosed Myeloma in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Garfall

Continued Evolution of Therapy for Patients With Newly Diagnosed MM

Dana-Farber Cancer Institute

C. Mo

Current Updates in the Management of NDMM

Integrity CE

J. Hillengass, S. Usmani

Myeloma Case Discussion: Newly Diagnosed Patient Achieving MRD- sCR …

Total Health

J. Chandler, B. Randolph, M. Onciu

Recent Updates in the Treatment of Newly-Diagnosed Myeloma

Lisa Leypoldt